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Chromosome instability is a well documented feature of late
passage cultured fibroblasts derived from families conforming 
to the classical Li–Fraumeni syndrome (LFS) or the Li–Fraumeni-
like syndrome (LFL) and carrying heterozygous (mut/wt) ger-
mline mutations in TP53, the tumour suppressor gene encoding the
transcription factor p53 (Bischoff et al, 1990). Indeed, we found
chromosome instability to be a stronger characteristic of these
strains than other features such as increased longevity and resis-
tance to ionizing radiation damage (Boyle et al, 1998).
Chromosome instability was expressed as numerical and structural
chromosome changes and was temporally associated with loss of
the wtp53 allele in these strains. In three strains derived from two
Li–Fraumeni families in which no TP53 mutation has been found,
we also observed chromosome instability accumulating as cultures
approached the end of their lifespan.
We have now enlarged this study to 11 strains from 10 different
LFS or LFL families (collectively designated LF families) in
which no TP53 mutation was found despite direct sequencing of
all exons, intron–exon boundaries, 3′ and 5′ untranslated regions
and the promoter region (Varley et al, 1997) (Table 1). With the
exception of 121MA and 142MA, all strains were derived from
patients with experience of cancers typical of those in LF families
(e.g. sarcomas and breast cancer). Strain 121MA was included
from a cancer-unaffected brother of the cancer-affected donor of
122MA (family 119) because cells from the latter strain senesced
very rapidly and it was not possible to obtain metaphases in the
last 10% of its lifespan. Strain 142MA was the only
fibroblast strain available from family 96. It was derived from a
cancer-unaffected male, whose sister and mother had typical LFS
tumours (osteosarcoma and leiomyosarcoma respectively), and
although incompletely sequenced (footnote, Table 1) had behaved
as a non-TP53 mutation carrier in several functional assays.
Strains were grown from the earliest available stocks in
Minimal Essential Medium plus 15% foetal calf serum (Gibco)
and repeatedly split 1:3 at confluence until senescent. The
maximum number of apparent population doublings was calcu-
lated for each strain. Metaphase preparations were made at inter-
vals according to standard methods and were stained with Giemsa.
All metaphases were scored for numerical aberrations and those
with a near diploid chromosome number (45 or 46 chromosomes)
were karyotyped and also scored for unstable structural chromo-
some aberrations. Accurate chromosome counts were made up to
80 chromosomes; cells with > 80 were classified as ‘polyploid’.
At each sampling time the percentage of the maximum number
of population doublings (PD max in Table 1) was calculated for
each strain (PD% in Table 2). The normal range of each parameter
was defined by seven strains from normal healthy donors sampled
between 88–100% of their maximum PD. These were compared
with LF strains sampled in the last 10% of their lifespan.
Aberration yields for individual LF strains were considered to be
significantly above normals if they exceeded the normal mean plus
three standard deviations.
The mean ± SD lifespan of the nine LF strains from cancer-
affected individuals (Table 1) was 30.7 ± 12.9 PD compared to
either 30.3 ± 7.1 for the seven normal strains in this study
(Mann–Whitney U test, P = 0.96) or 26.6 ± 17.0 PD for a larger
group of 18 normals (P = 0.29). This confirms our earlier observa-
tion that the in vitro lifespans of LF strains without TP53 muta-
tions are not significantly different to those of normal strains, in
contrast to TP53 mutation strains (Boyle et al 1998).
An abnormal cell was defined as one not having a normal set of
46 chromosomes, i.e. one showing either numerical or structural
changes or both. Because only solid staining (Giemsa) was used,
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doi: 10.1054/ bjoc.2000.1444, available online at http://www.idealibrary.com on only the numerical and unstable aberrations (readily detected after
solid staining) are tabulated in Table 2. However, in the ‘Abnor-
mal cells’ column we have included additional, easily identifi-
able, stable changes such as marker chromosomes, trisomies and
monosomies. Further details of these are given as footnotes. The
frequencies of abnormal cells in the last 10% of the lifespan of five
of 10 LF strains (115MA, 126MA, 127MA, 140MA, 142MA)
were significantly greater than normals, and values of three others
(107MA 121MA, 128MA) fell outside the range of normal
controls but did not reach significance. Exceptions that fell within
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Table 1 Origin and clinical characteristics of the fibroblast strains
Strain Familya Person Type Cancer Sex Age at Therapyb PDc
experience biopsy max
79MA 81 III-5 LFS Affected F 70 No 38
107MA 353 III-3 LFL Affected F 35 No 31
115MA 82 IV-5 LFS Affected M 22 Yes (7 y) 18
121MA 119 III-2 LFS Unaffected M 43 No 24
122MA 119 III-1 LFS Affected M 46 Yes (13 y) 15
126MA 88 II-2 LFS Affected M 29 No 53
127MA 338 IV-3 LFL Affected F 39 Yes (4 mo) 36
128MA 348 III-2 LFL Affected F 43 Yes (14 y) 43
140MA 21 LFS Affected F 14 Yes (7 y) 23
142MA 96d LFS Unaffected M 32 No 23
159MA 80 LFS Affected F 46 Yes (15 y) 19
aDetails of family, person, type and cancer experience are given in Varley et al (1997); bwhether or not radio- or chemo- therapy was received (number of years)
before biopsy; cMaximum number of population doublings achieved in vitro prior to cell senescence; dComplete analysis of TP53 sequence in this family has not
been possible due to the poor quality of DNA obtained from biopsy material, the mutation status is therefore unknown
Table 2 Chromosome aberrations in normal and TP53 non-mutation Li-Fraumeni fibroblasts
Strain Family PD PD Cells % Aneuploid % Unstable aberrations per 100 cellsa Abnormal
max (%) scored Polyploid cells (%)
Total Hypo Hyper Dics Ace Ring Cte Ctm Ctb/g Total
Normalsb Mean ± standard deviation 18.6 ± 3.9 18.3 ± 3.9 1.7 ± 3.7 1.3 ± 2.2 0.6 ± 1.0 1.7 ± 2.1 1.0 ± 1.3 0 0 5.1 ± 2.8 8.4 ± 2.4 22.0 ± 8.0
(n = 7) PD% = 88–100
Range 14–24 14–24 0–10 0–6 0–2 0–4 0–3 0 0 0–8 4–12 10.3–31.6
79MA 81 38 30 54 18.5 18.5 0 0 0 0 0 0 2 6 8 24.1
87 52 12 10 2 0 2 2 0 0 2 4 10 21.2
98 55 18 16 2 0 0 0 0 0 4 4 8 27.3
107MA 353 31 42 57 19 19 0 0 0 0 0 0 2 0 6 24.6
59 57 21 21 0 0 0 0 0 0 0 2 2 22.8
98 69 30 28 3 3 0 0 0 0 0 8 8 36.2
115MA 82 18 50 63 36 30 6402 0 0 0 4 6 9 1 . 7 c
52 60 27 27 0 0 0 0 0 0 0 8 8 91.7c
77 54 15 11 4 0 0 0 0 0 2 8 10 100.0d
86 77 47 42 6404 0 0 0 2 8 100.0d
100 62 32 29 3 0 0 2 0 0 0 6 8 94.0c
121MA 119 24 37 59 27 25 2 2 0 2 0 0 0 4 6 33.0
94 64 36 2 7 9304 0 0 2 2 8 43.9
122MA 119 15 67 56 24 21 3 3 0 2 0 0 0 2 4 27.6
126MAb 88 53 28 57 15 13 2 2 0 0 0 0 0 10 10 31.0
76 47 15 13 2 0 0 0 0 0 0 4 4 19.1
99 10 90 30 60 0 280 50 40 10 60 40 480 100.0
127MA 338 36 23 54 11 11 0 0 0 4 0 0 0 2 6 16.7
56 57 25 25 0 2 0 8 0 2 06 16 35.1
83 70 41 41 0 11 0 10 00 2 10 22 52.9
100 50 74 74 0 22 11.1 11.1 0 0 0 5.6 27.8 89.0
128MA 348 43 23 60 26 25 1 1 0 2 0 0 0 6 8 32.6
98 61 34 30 5500 0 0 0 8 8 3 9 . 0
140MA 21 23 39 53 13 13 0 0 0 0 0 0 0 4 4 92.0c
91 64 99 97 2008 0 0 4 4 16 100.0c
142MA 96 23 52 55 24 24 0 0 0 0 0 0 0 14 14 93.0f
97 98 95 82 13 10 4 20 20 2 2 30 95.0
159MAb 80 19 100 50 26 16 10 0 12 0 0 0 0 2 14 26.0
aScored in cells with 45 or 46 chromosomes; standard abbreviations according to ISCN (1995) Disc = dicentrics; Ace = acentrics; Ring = ring chromosomes; 
Cte = chromatid exchange; Ctm = minute chromosome; Ctb/g = chromatid breaks and gaps; bData from Boyle et al (1998) and JMB (unpublished); cMajority of
cells had 45 or 46 chromosomes, but most had abnormal karyotypes; dMajority of cells had 45, 46 or 47 chromosomes, but most had abnormal karyotypes;
eOnly one cell with 46 chromosomes (abnormal), 49 cells with 45 chromosomes; fOnly 4/50 cells scored as ?normal, remainder with losses and gains of whole
chromosomes; Values in bold are greater than normal mean + 3 SD1138 JM Boyle et al
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the normal range were 79MA and 159MA at > 90% PD. Although
the frequency of abnormal cells in strain 122MA at 67% PD (the
latest successful sampling time, see above) was within the normal
range, that of strain 121MA, from an unaffected blood relative,
was outside the normal range at early (37% PD) and late (94% PD)
population doublings.
Numerical changes were the major aberration type observed.
The relatively high frequency of hypoploidy in normals (mean
18.6%) may have included cells that had lost chromosomes dur-
ing preparation of metaphases, although care was taken during
analysis to exclude any obviously broken cells. Nevertheless, in
preparations of LF strains prepared in the same way and scored
by the same experienced cytogeneticist, a significant excess of
hypoploidy occurred in five strains (126MA, 127MA, 128MA,
140MA, 142MA), and values for three other strains (107MA,
115MA, 121MA) were above the normal range. Only strains
126MA and 142MA showed excess hyperploidy, (47–79 chromo-
somes) and strains 127 MA and 142MA had excess ‘polyploid’
cells.
Four of the five strains whose abnormal cell frequencies were
significantly above the normals exhibited levels of unstable
structural aberrations that were also significantly above the nor-
mal level (126MA, 127MA, 140MA, 142MA). The frequency in
159MA was outside the normal range.
Four strains showed unusual features. Strain 126MA showed
dramatically higher frequencies of structural aberrations at 99%
PD compared to 76% PD and compared to any of the other strains.
Although only 10 cells could be scored at 99% PD, all of these
were grossly abnormal. These high levels of damage were compa-
rable to those of late passage TP53 heterozygous LF strains (Boyle
et al. 1998). Strain 115MA was exceptional in that although most
cells contained 45, 46 or 47 chromosomes, monosomy, trisomy
and marker chromosomes were frequent with the result that virtu-
ally all cells had abnormal karyotypes, even at the earliest passage
scored (50% PD). The same was true for early passage (39% PD)
140MA cells, which by 91% PD had evolved so that 49 of 64
(77%) of cells had 45 chromosomes and only 1 of 64 had 46 chro-
mosomes. Strain 142MA also had a high frequency of cells with
deletions and duplications of chromosomes.
These results consolidate the conclusion of our earlier study
(Boyle et al, 1998) that chromosome instability, expressed mainly
as increased hypoploidy, is a feature of LF cells from families
without TP53 mutations that may be a major factor contributing to
the cancer proneness of these families. The present study empha-
sizes the point that genetic instability increases with cell age, and,
in several cases, is increased dramatically just prior to senescence.
However, there are also cases (79MA, 159MA) where this
dramatic increase is not seen, implying that the expression of insta-
bility is heterogeneous within this class of LF strains. These obser-
vations are similar, but generally expressed less strongly, to those
seen in LF cells carrying germline TP53 mutations. The latter situ-
ation was associated with loss of the remaining wild-type p53
allele and in several cases was associated with clonal losses of
chromosome segments that were observed by comparative genome
hybridization (Burt et al, 2000). More detailed cytogenetic studies
will be necessary to establish whether clonal events are also
involved in the genetic instability of LF cells from families
without  TP53 mutations, and whether the spectrum of clonal
changes is the same in both LF groups.
In TP53 heterozygous LF strains, genetic instability correlates
well with resistance to the clonogenic killing effect of ionizing
radiation (IR) given at low dose rate (LDR, ~1 cGy per min)
(Sproston et al, 1996; Boyle, 1998). Radiation survival data for
non-mutation strains is less complete, but strain 79MA (family 81)
and two strains from family 80 (146MA, 154MA), comparable to
159MA, showed no resistance (Boyle et al 1998) and no genetic
instability. In contrast, three strains (126MA, 127MA, 142MA)
that are resistant to LDR IR (Boyle et al, 1998 and unpublished
data) all show genetic instability. In LF cells with TP53 mutations
a similar correlation was found to be consistent with the hypoth-
esis that such cells can tolerate a greater degree of genetic damage
than normal cells, due to reduced genome surveillance (Lane,
1992; Williams et al, 1997).
In support of this hypothesis, genetic instability was also found
to be associated with a compromised cell-cycle G1 checkpoint in
TP53 heterozygous LF strains, but to be normal in cells from non-
mutation families (Boyle et al, 1999). The possibility that other
cell-cycle checkpoints may be compromised in non-mutation
families is under examination and recently a germline mutation in
the checkpoint kinase gene, hChk2, was identified in family 81
(Bell et al 1999) and is present in 79MA (JMV, unpublished
results). So far we have been unable to detect an abnormal pheno-
type in fibroblasts associated with this mutation.
ACKNOWLEFDGEMENT
This work was funded by the Cancer Research Campaign.
REFERENCES
Bell D, Szydlo T, Kang D, Wahrer D, Shannon KE, Lubratovitch M, Versilis JJ,
Isselbacher KJ, Birch JM, Varley JM, Li FP, Garber JE and Haber DA (1999)
Heterozygous germline mutations in hChk2l are a cause of Li-Fraumeni
syndrome. Science 286: 2528–2531
Bischoff FZ, Yin SO, Pathak S, Grant G, Siciliano MJ, Giavanella BC, Strong LC
and Tainsky MA (1990) Spontaneous abnormalities in normal fibroblasts from
patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalisation.
Cancer Res 50: 7979–7984
Boyle JM, Mitchell ELD, Greaves MJ, Roberts SA, Tricker K, Varley JM, Birch JM
and Scott D (1998) Chromosome instability is a predominant trait of fibroblasts
from Li-Fraumeni families. Br J Cancer 77: 2181–2192
Boyle JM, Greaves MJ, Camplejohn RS, Birch JM, Roberts SA and Varley JM
(1999) Radiation-induced G1 arrest is not defective in fibroblasts from Li-
Fraumeni families without TP53 mutations. Br J Cancer 79: 1657–1664
Burt EC, James LA, Greaves MJ, Birch JM, Boyle JM and Varley JM (2000)
Genomic alterations associated with loss of heterozygosity for TP53 in Li-
Fraumeni Syndrome fibroblasts. Br J Cancer (in press)
ISCN (1995) An international system for human cytogenetic nomenclature.
Mitelman F (ed) S Karger: Basel
Lane DP (1992) Cancer. P53, guardian of the genome. Nature 358: 15–16
Sproston ARM, Boyle JM, Highway J, Birch JM and Scott D (1996) Li-Fraumeni
fibroblasts are resistant to low dose-rate irradiation. Int J Radiat Biol 70:
145–150
Varley JM, McGown G, Thomcroft M, Santibanez-Koref MF, Kelsey AM, Tricker
KJ, Evans DGR and Birch JM (1997) Germline mutations of TP53 in Li-
Fraumeni families: an extended study of 39 families. Cancer Res 57:
3245–3252
Williams KJ, Boyle JM, Birch JM, Norton JD and Scott D (1997) Cell cycle arrest
defect in Li-Fraumeni syndrome: a mechanism of cancer predisposition?
Oncogene 14: 277–282